| Chemohormonal therapy in metastatic hormone-sensitive prostate cancer CJ Sweeney, YH Chen, M Carducci, G Liu, DF Jarrard, M Eisenberger, ... New England Journal of Medicine 373 (8), 737-746, 2015 | 2865 | 2015 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1827 | 2020 |
| Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients JS Ko, AH Zea, BI Rini, JL Ireland, P Elson, P Cohen, A Golshayan, ... Clinical cancer research 15 (6), 2148-2157, 2009 | 975 | 2009 |
| Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial CE Kyriakopoulos, YH Chen, MA Carducci, G Liu, DF Jarrard, NM Hahn, ... Journal of Clinical Oncology 36 (11), 1080, 2018 | 942 | 2018 |
| Requirements for CD1d Recognition by Human Invariant Vα24+ CD4−CD8− T Cells M Exley, J Garcia, SP Balk, S Porcelli The Journal of experimental medicine 186 (1), 109-120, 1997 | 654 | 1997 |
| Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients JH Finke, B Rini, J Ireland, P Rayman, A Richmond, A Golshayan, L Wood, ... Clinical Cancer Research 14 (20), 6674-6682, 2008 | 516 | 2008 |
| Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib BI Rini, I Tamaskar, P Shaheen, R Salas, J Garcia, L Wood, S Reddy, ... Journal of the National Cancer Institute 99 (1), 81-83, 2007 | 465 | 2007 |
| Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial AJ Armstrong, S Halabi, T Eisen, S Broderick, WM Stadler, RJ Jones, ... The Lancet Oncology 17 (3), 378-388, 2016 | 411 | 2016 |
| Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma B Raychaudhuri, P Rayman, J Ireland, J Ko, B Rini, EC Borden, J Garcia, ... Neuro-oncology 13 (6), 591-599, 2011 | 382 | 2011 |
| Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer H Zargar, PN Espiritu, AS Fairey, LS Mertens, CP Dinney, MC Mir, ... European urology 67 (2), 241-249, 2015 | 298 | 2015 |
| Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer Z Li, AC Bishop, M Alyamani, JA Garcia, R Dreicer, D Bunch, J Liu, ... Nature 523 (7560), 347-351, 2015 | 285 | 2015 |
| Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy TK Choueiri, JA Garcia, P Elson, M Khasawneh, S Usman, AR Golshayan, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 282 | 2007 |
| Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III … C Sweeney, YH Chen, MA Carducci, G Liu, DF Jarrard, MA Eisenberger, ... Journal of Clinical Oncology 32 (15_suppl), LBA2-LBA2, 2014 | 270 | 2014 |
| Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy AR Golshayan, S George, DY Heng, P Elson, LS Wood, TM Mekhail, ... Journal of Clinical Oncology 27 (2), 235-241, 2009 | 267 | 2009 |
| Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial BI Rini, TB Dorff, P Elson, CS Rodriguez, D Shepard, L Wood, J Humbert, ... The Lancet Oncology 17 (9), 1317-1324, 2016 | 265 | 2016 |
| Recent progress in the management of advanced renal cell carcinoma JA Garcia, BI Rini CA: a cancer journal for clinicians 57 (2), 112-125, 2007 | 262 | 2007 |
| Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma AA Thomas, BI Rini, BR Lane, J Garcia, R Dreicer, EA Klein, AC Novick, ... The Journal of urology 181 (2), 518-523, 2009 | 239 | 2009 |
| Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies G Gravis, JM Boher, YH Chen, G Liu, K Fizazi, MA Carducci, S Oudard, ... European urology 73 (6), 847-855, 2018 | 236 | 2018 |
| CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Vα24JαQ T cell receptor α chains M Exley, S Porcelli, M Furman, J Garcia, S Balk The Journal of experimental medicine 188 (5), 867-876, 1998 | 228 | 1998 |
| CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes M Exley, J Garcia, SB Wilson, F Spada, D Gerdes, SMA Tahir, KT Patton, ... Immunology 100 (1), 37-47, 2000 | 217 | 2000 |
Brian RiniVanderbilt University Medical CenterVerified email at vumc.org
